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Abstract
Background: There is an overwhelming burden of cardiovascular disease, type 2 diabetes and chronic kidney
disease among Indigenous Australians. In this high risk population, it is vital that we are able to measure accurately
kidney function. Glomerular filtration rate is the best overall marker of kidney function. However, differences in
body build and body composition between Indigenous and non-Indigenous Australians suggest that creatinine-
based estimates of glomerular filtration rate derived for European populations may not be appropriate for
Indigenous Australians. The burden of kidney disease is borne disproportionately by Indigenous Australians in
central and northern Australia, and there is significant heterogeneity in body build and composition within and
amongst these groups. This heterogeneity might differentially affect the accuracy of estimation of glomerular
filtration rate between different Indigenous groups. By assessing kidney function in Indigenous Australians from
Northern Queensland, Northern Territory and Western Australia, we aim to determine a validated and practical
measure of glomerular filtration rate suitable for use in all Indigenous Australians.
Methods/Design: A cross-sectional study of Indigenous Australian adults (target n = 600, 50% male) across 4 sites:
Top End, Northern Territory; Central Australia; Far North Queensland and Western Australia. The reference measure
of glomerular filtration rate was the plasma disappearance rate of iohexol over 4 hours. We will compare the
accuracy of the following glomerular filtration rate measures with the reference measure: Modification of Diet in
Renal Disease 4-variable formula, Chronic Kidney Disease Epidemiology Collaboration equation, Cockcroft-Gault
formula and cystatin C- derived estimates. Detailed assessment of body build and composition was performed
using anthropometric measurements, skinfold thicknesses, bioelectrical impedance and a sub-study used dual-
energy X-ray absorptiometry. A questionnaire was performed for socio-economic status and medical history.
Discussion: We have successfully managed several operational challenges within this multi-centre complex clinical
research project performed across remote North, Western and Central Australia. It seems unlikely that a single
correction factor (similar to that for African-Americans) to the equation for estimated glomerular filtration rate will
prove appropriate or practical for Indigenous Australians. However, it may be that a modification of the equation in
Indigenous Australians would be to include a measure of fat-free mass.
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Indigenous Australians have rates of cardiovascular
d i s e a s e( C V D )m o r t a l i t ys o m e7 - 1 0t i m e sh i g h e rt h a n
non-Indigenous Australians aged 25-64 years, a preva-
lence of diabetes some 10 times higher (age 20-50
years), new cases of end stage kidney disease (ESKD)
10-15 times higher and life expectancy 15-20 years
shorter [1-3]. Type 2 diabetes is common amongst
Indigenous Australians with ESKD: 77% of Indigenous
Australians with new ESKD in 2007 compared to 33%
of non-Indigenous Australians have Type 2 diabetes as
a comorbidity [4]. Rates of ESKD in Indigenous Aus-
tralians are disproportionately highest in those in cen-
tral and northern Australia [5]. This group of people is
widely dispersed and heterogenous: they live in urban,
regional and remote settings and have wide variation
in diet, body habitus, genetic admixture and socioeco-
nomic background [6-8].
With the serious burden of ESKD in Indigenous Aus-
tralians it is essential to be able to assess accurately
r e n a lf u n c t i o ni nt h e s ep o p u l a tions. Glomerular filtra-
tion rate (GFR) is the best overall marker of renal func-
tion in people with healthy or diseased kidneys [9] and
is an independent predictor of renal and cardiovascular
events [10,11]. At present there are no validated meth-
ods for estimating GFR in Indigenous Australians
[12,13]. Differences in body build and body composition
between Indigenous and non-Indigenous Australians
suggest that creatinine-based estimates of GFR (eGFR)
derived for European populations may not be appropri-
a t ef o rI n d i g e n o u sA u s t r a l i a n s ,a sm u s c l em a s si sak e y
determinant of serum creatinine levels. Compared to
Australians of European background, Indigenous Aus-
tralians from remote central and northern Australia
have more fat for a given weight or BMI [7].
It is increasingly recognised that current creatinine-
based formulae used to estimate GFR might not be gen-
eralisable across all clinical presentations [14,15]. They
also lack validation in ethnic populations apart from
Caucasians and African Americans [12,14]. The Modifi-
cation of Diet in Renal Disease 4-variable formula
(MDRD) was derived from a study population with
impaired renal function; and thus is less accurate within
a “healthy range” GFR. To address this issue a revised
equation (Chronic Kidney Disease Epidemiology Colla-
boration, CKD-EPI) has been described [16].
An alternate approach is to use a different analyte
from creatinine to estimate renal function and develop
GFR prediction equations. Serum cystatin C has been
proposed as a simple, reliable and accurate marker of
GFR when compared to creatinine-based methods
[17,18]. Although there is some evidence to suggest that
cystatin C levels might be influenced by extra-renal
factors, numerous studies have suggested that cystatin C
levels or GFR estimates based on cystatin C levels alone
are more accurate indices of renal function than creati-
nine-based methods [19]. However, at this time cystatin
C assays are not routinely available, they are consider-
ably more expensive than creatinine assays and are not
yet fully standardised. Thus for the immediate future,
optimisation of creatinine-based methods remains
important.
T h ea i mo ft h ep r e s e n ts t u d yi st oe v a l u a t ea n d
improve if necessary the accuracy and precision of eGFR
estimates in Indigenous Australians, taking into account
the heterogeneity in body build and body composition
across different populations. The study’sh y p o t h e s e sa r e :
(i) that differences in body build and body composition
between Indigenous and non-Indigenous Australians
will affect the validity of creatinine-based estimated
measures of GFR (using existing predictive equations)
and that accuracy of estimates of GFR will vary across
different Indigenous population groups; and (ii) that a
more accurate assessment of GFR will be obtained by a
formula involving serum creatinine and percent fat free
mass (obtained by a simple, validated bioimpedance
measurement) or by using an alternative biochemical
measure such as cystatin C. It is anticipated that this
will be of use in both Indigenous and non-Indigenous
Australians of variable body builds, particularly at
GFR>60 ml/min/1.73 m
2.
Methods/Design
Setting & location
Participants were recruited from 4 geographical regions:
Top End (of Northern Territory, Australia), Central
Australia, Far North Queensland and Western Australia.
These regions were chosen as resident Indigenous Aus-
tralians bear a disproportionately larger burden of ESKD
than those from other regions of Australia. Within these
four regions, the following Aboriginal Medical Services
or health facilities were recruitment centres: Top End -
Royal Darwin Hospital, Danila Dilba Health Services
(Darwin), Bagot Community Health Centre (Darwin),
Wurli Wurlinjang (Katherine), Ngalkunbuy Health Ser-
vice (Miwatj Health Aboriginal Corporation, Galiwinku),
Katherine District Hospital, Gove (Nhulunbuy) District
Hospital; Central Australia-A l i c eS p r i n g sH o s p i t a l ,
Tennant Creek Hospital, Central Australian Aboriginal
Congress, Anyinginyi Health Aboriginal Corporation
(Tennant Creek), Amooguna Health Centre, Titjikala
Health Centre; Western Australia - Bega Garnbirringu
Health Service Aboriginal Corporation (Kalgoorlie),
Kimberley Aboriginal Medical Services; Far North
Queensland - Wuchopperen Health Service (Cairns),
Thursday Island Hospital, Cairns Base Hospital Diabetes
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Northern Penninsula Area Community Council.
Participants and recruitment
Participants were Indigenous Australians (target n = 600
with equal numbers of males and females) aged 16 years
and above, from urban, rural and remote regions of
Northern and Central Australia across the following 5
strata:
(i) “healthy” group: nil diabetes, hypertension,
chronic kidney disease (CKD), albuminuria;
(ii) participants with diabetes or albuminuria &
eGFR (MDRD-4) >90 ml/min/1.73 m
2;
(iii) eGFR 60-90 ml/min/1.73 m
2;
(iv) eGFR 30-59 ml/min/1.73 m
2;
(v) eGFR <15-29 ml/min/1.73 m
2.
Indigenous Australians fulfilled the definition of
‘Aboriginal and/or Torres Strait Islander’ according to
t h es t a n d a r dm e t h o du s e di nN a t i o n a lC e n s u sd a t ac o l -
lection: “1) is of Aboriginal and/or Torres Strait Islander
descent; 2) identifies as an Australian Aboriginal and/or
Torres Strait Islander; and 3) is accepted as such by the
community in which he or she lives or has lived”.
Exclusion criteria were: participants with rapidly chan-
ging kidney function, participants receiving dialysis,
women who were pregnant or breastfeeding and people
with a history of allergy or adverse reaction to iodine-
based contrast media.
Participants with CKD and/or diabetes were recruited
from participating Aboriginal Medical Services and the
nephrology, endocrinology and outreach kidney disease
clinics associated with Royal Darwin Hospital, Alice
Springs Hospital, Cairns Base Hospital and the Royal
Perth Hospital. The identification and recruitment of
the “healthy” group was through community networks,
staff members of health services, word-of-mouth, self
referral and family members of participants.
Funding
Major funding was provided by the National Health and
Medical Research Council of Australia (NHMRC, pro-
ject grant #545202). Prior to award of this grant, pilot
funding was received from: Kidney Health Australia, the
Colonial Foundation of Australia and Menzies School of
Health Research. Additional funding for equipment was
received from Rebecca L Cooper Medical Research
Grant.
Ethics
The study was approved by the joint Menzies School of
Health Research - Northern Territory Department of
Health and Community Services Human Research Ethics
Committee. The project was considered and approved by
both the Aboriginal sub-committee, which has absolute
right of veto, and by the main committee. The study was
also approved by the following Human Research Ethics
Committees: Central Australian Human Research Ethics
Committee, Western Australian Aboriginal Health Infor-
mation and Ethics Committee, Royal Perth Hospital
Ethics Committee and Cairns and Hinterland Health Ser-
vices District Human Research Ethics Committee.
Staff
Six people were employed on contracts over the course
of the study. Of these, four were Indigenous and two
were non-Indigenous. Additional people were employed
on a casual basis during visits to discrete communities;
these community members acted as local facilitators.
One post-graduate research student (who is Indigenous)
also participated in the study and was substantially
involved in data collection, whilst also making a signifi-
cant contribution to study profile and media relations.
The majority of staff members had prior health qualifi-
cations and experience: three were Aboriginal Health
Workers, two were registered nurses and the post-grad-
uate research student was a specialist nephrologist. The
staff member without a health qualification completed a
venipuncture certification course.
Consent
Potential participants were provided with written infor-
mation about the study, face-to-face discussion with a
staff member, and given an opportunity to ask ques-
tions. If required, an interpreter was employed to
explain all information relating to the study. Those who
indicated that they wished to participate were then
asked to complete and sign a consent form. Consent
was obtained using the NHMRC Guidelines for Ethical
Conduct in Aboriginal and Torres Strait Islander Health
Research. All participants were informed that their par-
ticipation was voluntary and that they could refuse or
withdraw from participating and need give no reasons
nor justification for their decision and that it would not
affect their medical care. A parent or guardian was
asked to sign the form as well if the participant was
under 18 years old. Participants were asked to give sepa-
rate consent for various elements of the study, includ-
ing: iohexol injection and blood and urine samples;
body measurements, body composition tests, blood pres-
sure and questionnaire; and collecting further informa-
tion from their medical records. They were also asked
whether they wanted a report sent to their primary
health care provider and whether their blood and urine
samples could be stored at Menzies School of Health
Research for 5 years and used for future studies related
to diabetes and kidney disease.
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Following confirmation of contact details and eligibility
and after obtaining informed consent, performance of
the reference measure of GFR and a health examination
was undertaken. This examination included: collection
of blood and urine samples; clinical and anthropometric
measurements; and the administration of questionnaires.
The performance of the reference measurement of GFR
required a minimum of 4 hours for participants, during
which time participants were given a healthy meal and
health promotion information. Details of the examina-
tion protocol:
(i) Reference measure of GFR: determined by mea-
suring the renal clearance of non-isotopic iohexol.
Iohexol was injected (5.445 ml, 300 mg/ml “Omni-
paque”) into an antecubital vein (or forearm/hand
vein if unable to use antecubital vein) and flushed
with 10 ml of normal saline. The volume of iohexol
includes the prime volume (0.445 ml) in the tubing
of the butterfly cannula used to inject the iohexol.
Extravasation was assessed by clinical inspection and
palpation of the injection site. If there was any evi-
dence of extravasation then the study was suspended
and the participant invited to return in 3-7 days for
assessment. Using the contralateral arm, venous
blood samples (5 ml) were collected for measure-
ment of iohexol at 120, 180 and 240 min post injec-
tion. Participants were closely supervised for possible
adverse reactions - whilst also receiving culturally
appropriate education about chronic kidney disease,
diabetes and/or healthy lifestyle.
Slope-intercept GFR was calculated from the
formula:
Slope-intercept GFR (mL/min) = k × Iohexol dose
(μg)/C0 (μg / m L )w h e r eki st h es l o p eo ft h es e m i l o g
plot of plasma Iohexol concentration versus time
(plotted using 3 points, refer above), and C0 is the cal-
culated Iohexol concentration at time zero (intercept).
This value was multiplied by 1.73 and divided by the
body surface area (BSA, calculated from the equation
BSA = 0.20247 × height (metres)
0.725 ×w e i g h t( k g )
0.425
[20]. The BSA-slope intercept GFR value (mL/min/1.73
m
2) was corrected by the Brochner-Mortensen correc-
tion factor = (0.990778 × GFR) - (0.001218 × GFR
2)
[21] providing a reference GFR value (mL/min/1.73 m
2).
(ii) Blood and urine measures:
a. Serum creatinine measurements: performed
both locally and at a central laboratory (The
Department of Laboratory Medicine, Austin
Health).
b. Estimates of GFR/creatinine clearance (where
Scr is serum creatinine concentration in μmol/L,
age in years, weight in kg, eGFR in mL/min/1.73
m
2):
i. The adjusted MDRD-4 variable formula
(for creatinine measurements traceable to the
IDMS method and reported in μmol/L)
eGFR = 175 × [(Scr × 0.0113)
-1.154]×( a g e )
-0.203 ×
(0.742 if female) × (1.212 if African-American) [22]. The
above African-American “correction factor” was not
used for Indigenous Australians.
ii. The CKD-EPI formula [16]:
GFR = 141 × min(Scr × 0.0113/k, 1)
a × max(Scr ×
0.0113/k, 1)
-1.209 ×0 . 9 9 3
Age × 1.018 [if female] × 1.159
[if black], where Scr is serum creatinine, k is 0.7 for
females and 0.9 for males,
a is -0.329 for females and
-0.411 for males, min indicates the minimum of Scr/k
or 1, and max indicates the maximum of Scr/k or 1. As
the correction factor “if black” applies to African-Ameri-
cans this was not used for Indigenous Australians.
iii. The Cockcroft-Gault (C-G) formula: [23]
Creatinine Clearance (mL/min) = { [140 - age] ×
weight/[Scr × 0.814]} × (0.85 if female) *also calculated
using ideal body weight (IBW) according to Therapeutic
Guidelines protocol when the patient is obese (BMI>30
kg/m
2). IBW = 50 kg + 0.9 kg/each cm over 152 cm (-
4.5 kg if female).
c. Cystatin C: non-fasting blood sample for mea-
surement of cystatin C levels collected on the
morning of iohexol clearance measurements.
d. Bloods (non-fasting) were taken with the 120
minute venous sample for iohexol: HbA1c, UEC,
lipids (total and HDL cholesterol), high sensitiv-
ity c-reactive protein were performed as standard
clinical care and analysed by local care providers.
Although a fasting blood sample would be pre-
ferable for assessment of lipids and creatinine it
was not practical in the setting of a renal or dia-
betes clinic. We therefore assessed non-fasting
total and HDL cholesterol and instructed partici-
pants not to consume meat on the day of the
examination prior to measurement of serum
creatinine. A subset of participants was asked
when they last ate a meal containing meat. The
light meal provided by study staff to participants
was given after the blood sample for creatinine
was taken. Additional serum (8 ml) was collected
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kers and a stored sample.
e. Urine: sample collected for microscopy and
culture and determination of the albumin to
creatinine ratio (ACR), performed as standard
clinical care and analysed by local care providers.
Urine cotinine was measured for quantitative
assessment of cigarette smoking (recent nicotine
consumption).
(iii) Clinical and anthropometric measures:
a. Blood pressure was measured three times after
the participant had been seated quietly for at
least 5 minutes. A Welch Allyn Spot Vital Signs
monitor (Welch Allyn Medical Products, Skanea-
teles Falls, USA) was used to measure systolic
and diastolic pressure, with three minutes
between readings. The pulse rate was recorded
with each reading.
b. Height was measured to the nearest 0.1 cm
using a wall-mounted stadiometer [24]. Partici-
pants were shoeless and wore light clothing.
They were instructed to stand facing forward
with weight distributed evenly on both feet, with
heels together and against the wall and arms
h a n g i n gl o o s e l yb yt h e i rs i d e s .T h ep a r t i c i p a n t ’s
head was positioned so that the Frankfort Plane
was horizontal. The participant was then
instructed to keep his or her eyes focused on a
point straight ahead, breathe in deeply, and
stretch to his or her fullest height, with heels still
o nt h eg r o u n d .T h em e a s u r i n gp l a t ew a st h e n
lowered onto the scalp until it rested firmly on
the top of the head and a reading to the nearest
0.1 cm was obtained and recorded. Following the
measurement of weight (as described below), a
second height measurement was obtained and
recorded, again to the nearest 0.1 cm. If the two
height measurements differed by more than 0.5
cm, a third measurement was taken and
recorded.
c. Weight in kilograms was measured using a
Seca digital portable scale (Model 767 and 841,
Seca Deutschland, Hamburg, Germany). Partici-
pants were asked to remove shoes, heavy gar-
ments, heavy jewellery, belts, loose change, keys,
mobile phones, and other items from pockets.
With the scales at zero, participants were asked
to stand on the centre of the base with feet
together, arms hanging loosely at the sides and
the head facing forward. Weight was recorded to
the nearest 0.1 kilogram. Two separate measure-
ments of weight were recorded and if the first
two differed at all then a third measurement of
weight was taken and recorded.
d. Waist and hip circumference were measured
in centimetres using a 2-metre non-stretch flex-
ible steel tape (Model W606PM Lufkin, Texas,
USA). Following removal of outer clothing, tight-
fitting garments, belts and heavy items from
pockets, participants were asked to stand com-
fortably erect in a relaxed manner, breathing
normally, with weight balanced evenly on both
feet, feet about 25-30 cm apart, and arms folded
across the chest. Waist and hip measurements
were taken alternately, with a minimum of two
measurements for each. All measurements were
taken and recorded to the nearest 0.1 centimetre.
If the first two measurements of either waist or
hip circumference differed by more than 1.0 cm,
then a third measurement was taken for waist or
hip, as relevant. Waist measurements were taken
directly on the participant’ss k i n .H i pm e a s u r e -
ments were taken over the participant’sc l o t h i n g ,
unless it was too tight or too baggy, in which
case the participant was asked to remove it. The
w a i s tw a sd e f i n e da st h em i d w a yp o i n tb e t w e e n
the iliac crest and the costal margin. These two
landmarks were identified and marked using a
felt tip pen, and the distance between them mea-
sured, with the midpoint marked. Once the tape
was around the participant’s body at the appro-
priate height and the tape was horizontal, the
participant was asked to breathe out gently. The
measurement was taken at the end of a normal
expiration, with the tape pulled snug but not
compressing the underlying soft tissue. If land-
marks were unable to be identified (in the occa-
sional very obese participant), waist
measurements were omitted. The hip circumfer-
ence was defined as the widest circumference
over the buttocks and below the iliac crest. The
hip circumference was measured at several posi-
tions (starting with the widest part of the but-
tocks when viewed from the side) and the widest
circumference recorded. Fatty aprons were not
included in the measurement of the hips. The
measurement was taken with the tape in a hori-
zontal position, and the tape was pulled to allow
it to maintain its position without causing
indentation.
e. Skinfold thickness assessment was performed
using Holtain calipers (Holtain Ltd, Crosswell,
Pembrokeshire, United Kingdom) at 4 sites bilat-
erally: peripheral (biceps, triceps) and central
(subscapular, suprailiac) [25]. Bilateral skinfold
measurements were performed in all participants
to ensure a site availability of longitudinal follow
up in the event of an arterio-venous fistula
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was marked using a felt-tip pen and each site
was identified as follows: biceps, anterior surface
of the biceps midway between the acromial pro-
cess and the elbow (antecubital fossa); triceps,
posterior surface of triceps at midpoint from the
acromial process (the most lateral and superior
aspect of the acromial head) to the olecranon;
subscapular, 2.5 cm infero-medially along a 45
degree line from inferior angle of the scapula;
suprailiac, 2.5 cm supero-medially along a 45
degree line from where the medial border of the
iliac crest tips in to the pelvis. The skin fold was
then firmly grasped by the thumb and index fin-
ger, using the pads at the tip of the thumb and
finger, and the skin fold gently pulled away from
the body. The caliper was placed perpendicular
to the fold, on the site marked, dialled up, at
approximately 1 cm below the finger and thumb.
While maintaining the grasp of the skin fold, the
caliper was released so that full tension was
placed on the skin fold. The dial was read to the
nearest 0.20 mm, 2 seconds after the grip was
fully released. Three measurements were taken at
each site were possible.
(iv) Whole body and segmental bioelectrical impe-
dance measurements (BIA) were performed at a sin-
gle frequency (50 kHz) using a four-terminal
impedance plethysmograph (Model DF50, Impe-
diMed, Brisbane). At study sites where a multi-fre-
quency bioimpedance spectroscopy instrument (BIS,
Model SFB7, ImpediMed, Brisbane) was available,
this was used. BIS technology allowed prediction of
body fluid volumes (intra- and extracellular water as
well as total body water) at the theoretically optimal
frequencies, providing precision and accuracy not
achievable using the simpler BIA device that oper-
ates at a single compromise frequency [26]. Predic-
tion of body fluid volumes is particularly important
in this study population at all stages of CKD - from
hyperfiltration with “normal” renal function to ESKD
(excluding dialysis). It is also worthy to note that
BIS provides measures of both intra-and extracellu-
lar water spaces and since muscle mass is strongly
related to intracellular water space this will provide
the opportunity to assess whether predictive power
can be increased by inclusion of this variable in GFR
formulae.
BIA/BIS was not performed if a participant had an
indwelling electrical device (such as cardiac pace-
maker). Participants were asked to void (empty blad-
der) prior to the assessment. Assessment was
performed after 5 minutes rest in the supine position
with limbs abducted away from the trunk, ensuring
that thighs were not touching. Eight electrodes (elec-
trocardiograph-style gel electrodes) were placed on
bilateral dorsal surfaces of hands and feet (two elec-
trodes on each hand and foot); after the surface was
cleansed with an alcohol wipe. At the wrist, the
proximal electrode was placed in the midline of the
ulnar styloid process and the distal electrode was
placed 5 cm distal to the proximal electrode. At the
ankle, the proximal electrode was placed at the mid-
point between the medial and lateral malleoli and
the distal electrode was placed 5 cm distal to the
proximal electrode. Whole body and segmental
impedance measurements were according to pre-
viously described methods [27].
(v) DXA Sub-study: Further assessment of body
composition by dual-energy X-ray absorptiometry
(DXA) assessment of total body fat mass, lean mass,
bone mineral content and bone density was per-
formed according to standard techniques in sites
where this imaging technique was available: Darwin,
Perth and Torres Strait. DXA is a reference method
for assessing body composition but impedance
methods, particularly inexpensive single frequency
BIA, are much more practical in remote locations
(where DXA is indeed not possible/available).
Hence, the aim of the sub-study comparing DXA
and BIA was to see if BIA is a reasonable substitute
for DXA, thereby enabling body composition assess-
ment in remote communities. In the present study
all participants had body composition measured by
BIA or BIS and anthropometry, and a subset (Dar-
win, Perth and Torres Strait) also had DXA mea-
surements. The DXA data will be used to validate
the impedance data.
(vi) Questionnaires:
a. Medical history & medications - self report
and from medical records (where available)
including assessment of cigarette smoking: cur-
rent status, past history and self-reported
quantity.
b. Assessment of socio-economic status and
related personal details by brief questionnaire:
usual place of residence, first language, language
spoken at home, ethnicity of grandparents,
income source, ever worked, education level,
number of bedrooms and occupants in house,
housing tenure and landlord type.
Feedback to participants was provided at the end of
the examination. Brief intervention regarding diet, physi-
cal activity and health behaviours in particular smoking,
was provided. Participants with unexpected abnormal
results were referred immediately to the appropriate
health care provider. In addition, written results were
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manner to individual participants and to their nomi-
nated primary health care provider. Whenever possible,
participants with abnormal results were first contacted
by telephone or in person. The results packet was then
mailed or hand-delivered, as appropriate. A $50 gift
voucher to a local store was provided to participants
with their results as a gift of appreciation for their parti-
cipation in the study. Participants were not informed of
this gift prior to their participation in the study and it
was not used as an incentive to recruit participants to
the study. The gift was agreed upon by study investiga-
tors after it was suggested by several key organisations
in our community consultation: Kimberley Aboriginal
Medical Services Council and Wuchopperen Health Ser-
vice. Permission to give the gift was approved by all
relevant Human Research Ethics Committees.
Laboratory methods
Collected blood samples were centrifuged for 10 min at
3000 revolutions per min (RPM) within 4 hours of col-
lection. If unable to be centrifuged immediately, blood
was stored in a cool environment (fridge or esky) until
centrifugation occurred. Following centrifugation, sam-
ples were transported on ice to be stored at -80 degree
freezer. For samples collected in remote locations, sto-
rage for transportation was either on dry ice or in liquid
nitrogen ("Biological Shipper”,C r y o P a kS e r i e s ,T a y l o r -
Wharton, AL, USA). Samples collected on Thursday
Island, Queensland were stored at -30 degree for 2-14
days prior to transportation on dry ice to a -80 degree
freezer in Cairns.
Serum creatinine and other metabolite assays were
performed at each centre as part of standard clinical
care. The creatinine assay at each centre was confirmed
to have claimed traceability to the Isotope Dilution
Mass Spectrometry (IDMS) reference method. The
method and instrument used for measurement of each
biochemical measure performed at each site are outlined
in Table 1.
In addition, serum creatinine will be measured in all
samples at Austin Health, using the kinetic Jaffe method
and the Roche enzymatic method on a Beckman-Coul-
ter DxC 800 analyser (Fullerton, CA, USA). Beckman-
Coulter claims traceability for its Jaffe methods to the
IDMS reference method as it does for the Roche enzy-
matic method. The Roche enzymatic method has been
used as a reference method for the revision of the
MDRD formula for IDMS aligned assays [28] and has
undergone local independent validation [29]. Creatinine
will be measured by both the Jaffe and enzymatic meth-
ods as many laboratories in Australia measure creati-
nine with a Jaffe method. This approach will allow for a
calibration and standardization of the Jaffe methods
against the enzymatic method and assessment of varia-
bility caused by the use of different routine methods.
Cystatin C will be measured using an automated parti-
cle-enhancing immunonephelometric assay on a BN II
instrument (Dade Behring, Marburg, Germany). The
intra- and interassay CVs for cystatin C were 2.58 and
3.95%, respectively, at a concentration of 1.54 mg/l.
Cystatin C measures will be transformed to a GFR
equivalent using the formua Cys-GFR = (86.7/cystatin C
-4.2). This Cys-GFR method has been validated as an
accurate marker of renal function across a wide-range
of GFR values using isotopic GFR measurements
(plasma dissapearance of
99 mTc-DTPA) as the refer-
ence method [18,30].
Iohexol was measured by Austin Health, Melbourne
using a validated HPLC assay modified from Niculescu-
Duvaz et al [31]. Plasma samples were extracted using a
solution of 5% perchloric acid containing internal stan-
dard (sodium diatrizoate). Chromatographic separation
was achieved using a Microsorb MV C18 5 μ column
(Varian Australia) and detection at 244 nm. Analyte
concentrations were calculated by comparison to multi-
point linear standard curves derived from plasma sam-
ples spiked to contain between 3.125 and 800 μg/mL
Iohexol (reference material, US Pharmacopoeia). The
lower limit of quantitation was 3.125 μg/mL. Intra- and
inter-assay performance was assessed using donor
plasma spiked with low (20 μg/mL), medium (100 μg/
mL) and high (400 μg/mL) concentrations of Iohexol.
Precision studies showed a Coefficient of Variation of
1.0% or less, and inaccuracy ± 4.5% or less.
Samples were stored for analysis at a later date for:
adiponectin and urine cotinine. For participants of the
DXA sub-study, samples have been stored for analysis
of 25-hydoxy Vitamin D and parathyroid hormone and
bone turnover markers.
Data handling and statistical methods
At the time of baseline assessment, data was collected
on paper forms and then entered into a Microsoft
Access database. Data from each site is stored securely
at Menzies School of Health Research. All statistical
analysis will be performed using the latest available
release of Stata software (Stata Corporation, College Sta-
tion, TX). The predictive performance of formulae
methods to estimate GFR will be compared to the refer-
ence GFR in terms of precision, bias and accuracy
according to the methods of Bland-Altman [32]. The
percentage of estimated GFR within 30% of measured
GFR will also be determined. If required, new prediction
equations will be developed in a “training sample”,w i t h
their veracity then being tested in a “validation” sample.
This will be achieved by randomly dividing the study
population into two subgroups, balanced across the five
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Page 8 of 11strata. Sample size was determined using the methods of
Bland-Altman [32,33] so that the limits of 95% confi-
dence intervals for the mean were equal to pre-specified
acceptability limits (a 10% difference in GFR was consid-
ered to be acceptable). Sample size was calculated at 600
Indigenous participants across 4 sites (approximately
150 at each site), with considerable heterogeneity in
body builds and composition expected both within and
between sites. Regression equations will be derived
using a similar approach to that used to develop the ori-
ginal MDRD equations [34]. In addition, for the body
composition substudy (DXA vs. BIA), we will be able to
detect a difference ≥ 2 %i nf a tf r e em a s s( F F M )e s t i -
mated by the two methods, with a power >90% based
o nas a m p l es i z eo f3 0 0 ,a l p h a=0 . 0 5a n daC Vo f1 0 %
in FFM.
Detailed analysis of demographic, clinical, biochemical
and socioeconomic factors associated with CKD will
involve cross-sectional analysis of the associations
between these factors and current GFR. After determin-
ing univariate associations between variables, established
risk factors and variables with p < 0.2 on univariate ana-
lysis will be selected for entry into logistic regression
models using the backwards selection method, the out-
come variable being current GFR/CKD stage. The
degree of coupling of GFR and albuminuria will be
determined in participants with type 2 diabetes (after
accounting for the use of inhibitors of the renin-angio-
tensin system). We have recently shown that there is a
relatively high prevalence of non-albuminuric renal
insufficiency in non-Indigenous participants with type 2
diabetes [35] and preliminary evidence suggests that the
prevalence of non-albuminuric renal insufficiency is
lower in Indigenous than non-Indigenous diabetic Aus-
tralians [36].
Discussion
This study was designed with respect to what is practi-
cal and achievable in very remote regions of Northern,
Western and Central Australia. The choice of reference
measure of GFR was limited by our remote setting and
the available time of participants. Nuclear medicine
facilities are not available in the vast majority of sites
where this project was conducted. Study investigators
agreed that 4-hour plasma disappearance of iohexol was
t h em o s ta p p r o p r i a t er e f e r e n c em e a s u r eo fG F Rf o rt h e
remote setting. The benefits of this reference measure
are that it is practical, safe, stable and reproducible
[37,38]. In addition, several investigators had experience
with use of this measure in the non-Indigenous urban
setting (Melbourne) with accurate comparison to 99
mTc-DTPA in participants with diabetes [39]. Based on
previous experience of investigators in Indigenous health
research, we agreed that a reference measure that
required more than 4 hours of participants time would
not be practical or achievable.
A potential limitation of our study is the use of
Iohexol clearance from serum as the formal GFR mea-
surement as opposed to the use of urinary clearance of
iothalamate as the reference method used in the MDRD
and CKD-EPI studies [16,34]. Iohexol serum clearance
was however used in two studies used in the CKD-EPI
validation group [40,41] however the limitation of 4
hours for the studies has the potential to increase inac-
curacy in subjects with reduced GFR [40].
The study has encountered several operational chal-
lenges to date that have been successfully managed. The
first challenge is the significant labour intensity required
to recruit each participant and the associated expenses.
The proportion of eligible participants approached by
the study team, who subsequently consented to and suc-
cessfully completed the study, varied by site from
approximately 30% in urban centres to up to 70% in
some remote communities. We managed this challenge
by adapting recruitment sites to those that had a higher
success rate of obtaining complete data sets and expand-
ing networks and recruitment sites beyond health ser-
vice providers, e.g. Aboriginal Hostels Limited (provide
temporary and transit accommodation in urban and
regional centres).
The second challenge encountered by the eGFR study
team was to recruit a diverse sample of participants
including people living remotely and with poor access
to regular medical services. We managed this challenge
by: targeting a range of communities or regions; target-
ing remote-living individuals whilst they were visiting
regional centres (Darwin, Katherine and Nhulunbuy:
health and non-health service sites); and selection of
participants, stratified by study design, using electronic
health record data held by urban and remote health
services.
The third challenge was to conduct recruitment in
such a way to facilitate complete data collection, in par-
ticular complete 4 hour reference GFR measures. We
commenced recruitment of participants in association
with outpatient renal clinics (urban and regional). In the
regional setting other commitments for remote partici-
pants within the 4-hour duration of the study resulted
in non-completion of the reference GFR measures. Rea-
sons included the need to catch transport home (usually
a plane) or logistic constraints such as inclement
weather conditions. The study recruitment strategy was
subsequently changed so that the eGFR study team tra-
velled to remote communities to perform the study in
“batches” of 1-3 weeks duration. This strategy was
superior in terms of numbers of participants recruited
and proportion of participants with complete 4 hour
reference GFR measures.
Maple-Brown et al. BMC Public Health 2010, 10:80
http://www.biomedcentral.com/1471-2458/10/80
Page 9 of 11This study should provide evidence for clinical guide-
lines in a field where evidence is currently lacking: a
validated methodology to accurately assess renal func-
tion in diverse populations of Indigenous Australians.
We expect to determine a validated and practical mea-
sure of GFR suitable for use in all Indigenous Austra-
lians. This may be cystatin C or eGFR (using MDRD or
CKD-EPI formula with/without suitable revision). This
measure would enable development of appropriate pro-
tocols for investigation and management of CKD and
subsequent improvements in clinical practice. We
believe that the MDRD- or CKD-EPI derived method
(modified as appropriate) is likely to emerge as the
cheapest and most widely assessable means of estimat-
ing GFR in the immediate future. It seems unlikely that
a single correction factor (similar to that for Afro-Amer-
icans) is appropriate or practical for Indigenous Austra-
lians. However, it may be that a modification of the
MDRD or CKD-EPI equation for Indigenous Australians
( o rf o ra n yp o p u l a t i o n )w o u l db et oi n c l u d eam e a s u r e
of fat-free mass. This measure may be obtained by mea-
suring body composition using a simple, portable and
inexpensive method such as BIA, once it has been suita-
bly validated against DXA. Thereby this study may
improve the utility of eGFR, using a modified MDRD or
CKD-EPI formula, across different populations with dif-
ferent body builds and compositions. Our revised for-
mula for eGFR may indeed be of use for assessing
kidney function in the broader Australian community,
p a r t i c u l a r l yt h o s eo fv a r i a b l eb o d yb u i l d sa n d / o r
eGFR>60 ml/min/1.73 m
2.
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